Abstract
Background: There is limited information about the 6-min walk test (6MWT) in elderly patients with heart failure. We evaluated 6MWT and the effect of nebivolol on 6MWT from the SENIORS trial.
Methods and results: The SENIORS trial evaluated nebivolol versus placebo on death and hospitalisation in patients aged ≥ 70 years with heart failure. A total of 1982 patients undertook a 6MWT at baseline and 1716 patients at 6 months. Patients were divided into tertiles (≤ 200 m, 201 to ≤ 300 m and > 300 m) and to change in distance walked between baseline and 6 months (< 0 m, 0 to < 30 m and ≥ 30 m). The primary outcome was all-cause mortality and cardiovascular hospital admission. Secondary endpoint was all-cause mortality. Baseline walk distance of ≤ 200 m incurred a greater risk of the primary and secondary outcomes (HR 1.41, CI 95% 1.17–1.69, p < 0.001) and (HR 1.37, CI 95% 1.05–1.78, p = 0.019). A decline in walk distance over 6 months was associated with increased risk of clinical events. Nebivolol had no influence on change in walk distance over 6 months.
Conclusions: The 6MWT has prognostic utility in elderly patients. Those who walked less than 200 m were at highest risk. Nebivolol had no effect on 6MWT.
Original language | English |
---|---|
Pages (from-to) | 1193–1201 |
Number of pages | 9 |
Journal | Clinical Research in Cardiology |
Volume | 110 |
Issue number | 8 |
Early online date | 2 Nov 2020 |
DOIs | |
Publication status | Published - Aug 2021 |
Keywords
- Elderly
- Heart failure
- Prognosis
- Six-minute walk test
Profiles
-
Marcus Flather
- Faculty of Medicine and Health Sciences - Associate Tutor
- Norwich Medical School - Emeritus Professor
- Cardiovascular and Metabolic Health - Member
Person: Honorary, Research Group Member, Associate Tutor